Background: Melatonin has shown a protective effect against various oxidative damages in the nervous system. Our previous studies have also confirmed its effect on behavioral dysfunction of experimental rats and injury of striatal interneurons induced by 3-nitropropionic acid. The present study aimed to further determine the effect of melatonin on the injury of striatal projection neurons induced by 3-nitropropionic acid. Methods: Classic histology, immunohistochemistry, Western blotting and immunoelectron microscopy were applied in this study. Results: The results were as follows: (1) in the striatum, 3-nitropropionic acid induced a clear lesion area with a transition zone around it, in which both D1+ and D2+ fibers were decreased significantly. However, in the group with melatonin treatment, the striatal lesion area was smaller than in the 3-nitropropionic acid group and the loss of D1+ and D2+ fibers was less pronounced than in the 3-nitropropionic acid group. (2) Histochemical results showed that the dendritic spine density of striatal projection neurons was decreased more seriously after 3-nitropropionic acid treatment, whereas the loss of dendritic spines was less marked in the melatonin-treated group than in the 3- nitropropionic acid group. Immunoelectron microscopy showed that the density of D1+ and D2+ dendrites and spines was significantly decreased in the 3-nitropropionic acid group, and the loss of D1+ and D2+ spines as well as D2+ dendrites was significantly reversed by melatonin administration. (3) Western blotting showed that the expression level of projection neuron protein markers decreased more significantly in the 3-nitropropionic acid group than in the control group and increased significantly in the melatonin-treated group. Conclusions: The present results suggest that 3-nitropropionic acid induces serious injury of striatal projection neurons and that melatonin effectively protects against this pathological damage.

Keywords:
3-Nitropropionic acid, Melatonin, Projection neuron, Immunoelectron microscopy
1.
Lee J, Hwang YJ, Shin JY, Lee WC, Wie J, Kim KY, Lee MY, Hwang D, Ratan RR, Pae AN, Kowall NW, So I, Kim JI, Ryu H: Epigenetic regulation of cholinergic receptor M1 (CHRM1) by histone H3K9me3 impairs Ca(2+) signaling in Huntington's disease. Acta Neuropathol 2013;125:727-739.
2.
Cipriani S, Bizzoco E, Gianfriddo M, Melani A, Vannucchi MG, Pedata F: Adenosine A2A receptor antagonism increases nNOS-immunoreactive neurons in the striatum of Huntington transgenic mice. Exp Neurol 2008;213:163-170.
3.
Reiner A, Shelby E, Wang H, Demarch Z, Deng Y, Guley NH, Hogg V, Roxburgh R, Tippett LJ, Waldvogel HJ, Faull RL: Striatal parvalbuminergic neurons are lost in Huntington's disease: implications for dystonia. Mov Disord 2013;28:1691-1699.
4.
Deng YP, Lei WL, Reiner A: Differential perikaryal localization in rats of D1 and D2 dopamine receptors on striatal projection neuron types identified by retrograde labeling. J Chem Neuroanat 2006;32:101-116.
5.
Reiner A, Perera M, Paullus R, Medina L: Immunohistochemical localization of DARPP32 in striatal projection neurons and striatal interneurons in pigeons. J Chem Neuroanat 1998;16:17-33.
6.
Klivenyi P, Andreassen OA, Ferrante RJ, Dedeoglu A, Mueller G, Lancelot E, Bogdanov M, Andersen JK, Jiang D, Beal MF: Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. J Neurosci 2000;20:1-7.
7.
Jovicic A, Zaldivar Jolissaint JF, Moser R, Silva Santos M de F, Luthi-Carter R: MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific Huntington's disease-related mechanisms. PLoS One 2013;8:e54222.
8.
Erren TC, Reiter RJ, Piekarski C: Light, timing of biological rhythms, and chronodisruption in man. Naturwissenschaften 2003;90:485-494.
9.
Natarajan M, Reiter RJ, Meltz ML, Herman TS: Effect of melatonin on cell growth, metabolic activity, and cell cycle distribution. J Pineal Res 2001;31:228-233.
10.
Reiter RJ, Sainz RM, Lopez-Burillo S, Mayo JC, Manchester LC, Tan DX: Melatonin ameliorates neurologic damage and neurophysiologic deficits in experimental models of stroke. Ann NY Acad Sci 2003;993:35-47; discussion 48-53.
11.
Yoo YM, Yim SV, Kim SS, Jang HY, Lea HZ, Hwang GC, Kim JW, Kim SA, Lee HJ, Kim CJ, Chung JH, Leem KH: Melatonin suppresses NO-induced apoptosis via induction of Bcl-2 expression in PGT-beta immortalized pineal cells. J Pineal Res 2002;33:146-150.
12.
Nam E, Lee SM, Koh SE, Joo WS, Maeng S, Im HI, Kim YS: Melatonin protects against neuronal damage induced by 3-nitropropionic acid in rat striatum. Brain Res 2005;1046:90-96.
13.
Lanoix D, Lacasse AA, Reiter RJ, Vaillancourt C: Melatonin: the watchdog of villous trophoblast homeostasis against hypoxia/reoxygenation-induced oxidative stress and apoptosis. Mol Cell Endocrinol 2013;381:35-45.
14.
Naskar A, Manivasagam T, Chakraborty J, Singh R, Thomas B, Dhanasekaran M, Mohanakumar KP: Melatonin synergizes with low doses of L-DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism. J Pineal Res 2013;55:304-312.
15.
Montilla-Lopez P, Munoz-Agueda MC, Feijoo Lopez M, Munoz-Castaneda JR, Bujalance-Arenas I, Tunez-Finana I: Comparison of melatonin versus vitamin C on oxidative stress and antioxidant enzyme activity in Alzheimer's disease induced by okadaic acid in neuroblastoma cells. Eur J Pharmacol 2002;451:237-243.
16.
Tunez I, Munoz Mdel C, Feijoo M, Munoz-Castaneda JR, Bujalance I, Valdelvira ME, Montilla Lopez P: Protective melatonin effect on oxidative stress induced by okadaic acid into rat brain. J Pineal Res 2003;34:265-268.
17.
Mu S, OuYang L, Liu B, Zhu Y, Li K, Zhan M, Liu Z, Jia Y, Lei W: Protective effect of melatonin on 3-NP induced striatal interneuron injury in rats. Neurochem Int 2011;59:224-234.
18.
Tapias V, Cannon JR, Greenamyre JT: Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model. J Neurosci Res 2010;88:420-427.
19.
Gibb R, Kolb B: A method for vibratome sectioning of Golgi-Cox stained whole rat brain. J Neurosci Methods 1998;79:1-4.
20.
Flores G, Alquicer G, Silva-Gomez AB, Zaldivar G, Stewart J, Quirion R, Srivastava LK: Alterations in dendritic morphology of prefrontal cortical and nucleus accumbens neurons in post-pubertal rats after neonatal excitotoxic lesions of the ventral hippocampus. Neuroscience 2005;133:463-470.
21.
Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates. San Diego, Elsevier Academic Press, 1986.
22.
Deng YP, Wong T, Bricker-Anthony C, Deng B, Reiner A: Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington's disease mice. Neurobiol Dis 2013;60C:89-107.
23.
Bertran-Gonzalez J, Herve D, Girault JA, Valjent E: What is the degree of segregation between striatonigral and striatopallidal projections? Front Neuroanat 2010;4:136.
24.
Levey AI, Hersch SM, Rye DB, Sunahara RK, Niznik HB, Kitt CA, Price DL, Maggio R, Brann MR, Ciliax BJ: Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies. Proc Natl Acad Sci USA 1993;90:8861-8865.
25.
Spires TL, Grote HE, Garry S, Cordery PM, Van Dellen A, Blakemore C, Hannan AJ: Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice. Eur J Neurosci 2004;19:2799-2807.
26.
Andre VM, Fisher YE, Levine MS: Altered balance of activity in the striatal direct and indirect pathways in mouse models of Huntington's disease. Front Syst Neurosci 2011;5:46.
27.
Reiner A, Wang HB, Del Mar N, Sakata K, Yoo W, Deng YP: BDNF may play a differential role in the protective effect of the mGluR2/3 agonist LY379268 on striatal projection neurons in R6/2 Huntington's disease mice. Brain Res 2012;1473:161-172.
28.
Chang C, Crottaz-Herbette S, Menon V: Temporal dynamics of basal ganglia response and connectivity during verbal working memory. Neuroimage 2007;34:1253-1269.
29.
Chen L, Zhang X, Chen-Roetling J, Regan RF: Increased striatal injury and behavioral deficits after intracerebral hemorrhage in hemopexin knockout mice. J Neurosurg 2010;114:1159-1167.
30.
Evans AE, Kelly CM, Precious SV, Rosser AE: Molecular regulation of striatal development: a review. Anat Res Int 2012;2012:106529.
31.
Kreitzer AC, Malenka RC: Striatal plasticity and basal ganglia circuit function. Neuron 2008;60:543-554.
32.
Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr: Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985;44:559-577.
33.
Cicchetti F, Prensa L, Wu Y, Parent A: Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington's disease. Brain Res Brain Res Rev 2000;34:80-101.
34.
Tang TS, Chen X, Liu J, Bezprozvanny I: Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. J Neurosci 2007;27:7899-7910.
35.
Wickens JR, Arbuthnott GW, Shindou T: Simulation of GABA function in the basal ganglia: computational models of GABAergic mechanisms in basal ganglia function. Prog Brain Res 2007;160:313-329.
36.
Smith Y, Raju D, Nanda B, Pare JF, Galvan A, Wichmann T: The thalamostriatal systems: anatomical and functional organization in normal and parkinsonian states. Brain Res Bull 2009;78:60-68.
37.
Villalba RM, Lee H, Smith Y: Dopaminergic denervation and spine loss in the striatum of MPTP-treated monkeys. Exp Neurol 2009;215:220-227.
38.
Villalba RM, Smith Y: Striatal spine plasticity in Parkinson's disease. Front Neuroanat 2010;4:133.
39.
Smith Y, Villalba R: Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and Parkinsonian brains. Mov Disord 2008;23(suppl 3):S534-S547.
40.
Nithianantharajah J, Hannan AJ: Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease. Neuroscience 2013;251:66-74.
41.
Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, Low WC: Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad Sci USA 2002;99:10671-10676.
42.
Guidetti P, Charles V, Chen EY, Reddy PH, Kordower JH, Whetsell WO Jr, Schwarcz R, Tagle DA: Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production. Exp Neurol 2001;169:340-350.
43.
Ferrante RJ, Kowall NW, Cipolloni PB, Storey E, Beal MF: Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization. Exp Neurol 1993;119:46-71.
44.
Nithianantharajah J, Barkus C, Vijiaratnam N, Clement O, Hannan AJ: Modeling brain reserve: experience-dependent neuronal plasticity in healthy and Huntington's disease transgenic mice. Am J Geriatr Psychiatry 2009;17:196-209.
45.
Xie Y, Hayden MR, Xu B: BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. J Neurosci 2010;30:14708-14718.
46.
Weishaupt JH, Bartels C, Polking E, Dietrich J, Rohde G, Poeggeler B, Mertens N, Sperling S, Bohn M, Huther G, Schneider A, Bach A, Siren AL, Hardeland R, Bahr M, Nave KA, Ehrenreich H: Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res 2006;41:313-323.
47.
Caballero B, Vega-Naredo I, Sierra V, Huidobro-Fernandez C, Soria-Valles C, De Gonzalo-Calvo D, Tolivia D, Pallas M, Camins A, Rodriguez-Colunga MJ, Coto-Montes A: Melatonin alters cell death processes in response to age-related oxidative stress in the brain of senescence-accelerated mice. J Pineal Res 2009;46:106-114.
48.
Wang X: The antiapoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci Ther 2009;15:345-357.
49.
Martin M, Macias M, Escames G, Leon J, Acuna-Castroviejo D: Melatonin but not vitamins C and E maintains glutathione homeostasis in t-butyl hydroperoxide-induced mitochondrial oxidative stress. FASEB J 2000;14:1677-1679.
50.
Acuna-Castroviejo D, Coto-Montes A, Gaia Monti M, Ortiz GG, Reiter RJ: Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci 1997;60:PL23-PL29.
51.
Lahiri DK: Melatonin affects the metabolism of the beta-amyloid precursor protein in different cell types. J Pineal Res 1999;26:137-146.
52.
Wang X, Sirianni A, Pei Z, Cormier K, Smith K, Jiang J, Zhou S, Wang H, Zhao R, Yano H, Kim JE, Li W, Kristal BS, Ferrante RJ, Friedlander RM: The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity. J Neurosci 2011;31:14496-14507.
53.
Southgate GS, Daya S, Potgieter B: Melatonin plays a protective role in quinolinic acid-induced neurotoxicity in the rat hippocampus. J Chem Neuroanat 1998;14:151-156.
54.
Melchiorri D, Reiter RJ, Chen LD, Sewerynek E, Nistico G: Melatonin affords protection against kainate-induced in vitro lipid peroxidation in brain. Eur J Pharmacol 1996;305:239-242.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.